Capricor Stock Soars as FDA Resumes Deramiocel Review

Key Regulatory Development

Capricor Therapeutics Inc shares, ticker CAPR, surged 14.3% following an announcement from the company. The U.S. Food and Drug Administration has lifted a Complete Response Letter and resumed its review of the Biologics License Application for Deramiocel.

Situation Overview

The FDA classified the resubmission as Class 2 and established a new Prescription Drug User Fee Act target action date of August 22, 2026. According to Capricor, the agency has not identified any potential review issues in its response. The BLA is supported by positive results from the pivotal HOPE-3 Phase 3 clinical trial.

Market and Economic Impact

Deramiocel is an investigational cell therapy for Duchenne muscular dystrophy cardiomyopathy. It has the potential to become the first approved therapy to treat both skeletal and cardiac manifestations of the disease. Upon potential approval, Capricor expects to be eligible for a Priority Review Voucher, which holds significant financial value.

Summary Outlook

The resumption of the FDA review without new issues cited marks a significant positive step for Capricor Therapeutics. Investors will now be closely watching for further updates as the PDUFA target date approaches in 2026, which could significantly impact the company's valuation and market position.

FAQ

Q: Why did Capricor Therapeutics' stock increase?
A: The stock rose significantly after the U.S. FDA resumed the review of its Biologics License Application for the cell therapy Deramiocel.

Q: What is Deramiocel?
A: Deramiocel is an investigational cell therapy designed to treat Duchenne muscular dystrophy, specifically addressing both skeletal and cardiac symptoms.

Q: What is the next major milestone for Deramiocel?
A: The FDA has set a PDUFA target action date of August 22, 2026, which is the deadline for the agency to make a decision on the application.

Source: Investing.com